Esperion Reaches Settlement Agreement with Fifth ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) & NEXLIZET® (bempedoic acid & ezetimibe) Prior to April 19, 2040

Esperion announced a settlement agreement with Alkem Laboratories Ltd. to prevent the marketing of generic versions of NEXLETOL and NEXLIZET in the United States until April 19, 2040. This is the fifth ANDA filer to reach such an agreement with Esperion. Patent litigation against four remaining defendants (Aurobindo Pharma, MSN Pharmaceuticals, Renata Limited, and Sandoz Inc.) continues with uncertain outcomes.

02/17/2026, 8:00 AM • GlobeNewswire

Oncology Biosimilars Research and Global Forecast Report 2025-2030: Targeted Therapies, Emerging Market Expansion, and Novel Biosimilar Formulations Drive Growth

The global oncology biosimilars market is projected to grow from $9.6 billion in 2025 to $17.5 billion by 2030, at a CAGR of 12.6%. Growth is driven by rising cancer incidence, expiring biologic patents, and cost-effective treatment demand. AI and machine learning are being leveraged to streamline clinical trials and accelerate market entry, with key opportunities in breast, lung, and blood cancer indications across emerging markets.

02/04/2026, 12:54 PM • GlobeNewswire

Alvotech enters supply and commercialization agreements for Canada and Australia & New Zealand covering multiple biosimilar candidates

Alvotech announced supply and commercialization agreements with Sandoz for multiple biosimilar candidates in Canada, Australia, and New Zealand. In Canada, the agreement covers one ophthalmology biosimilar as a prefilled syringe, while the Australia and New Zealand agreement encompasses three biosimilar candidates in immunology and gastroenterology. Sandoz will handle regulatory filings and commercialization while Alvotech retains development, clinical activities, and manufacturing responsibilities.

02/02/2026, 3:00 AM • GlobeNewswire

Alvotech enters supply and commercialization agreements for Canada and Australia & New Zealand covering multiple biosimilar candidates

Alvotech announced supply and commercialization agreements with Sandoz for multiple biosimilar candidates in Canada, Australia, and New Zealand. In Canada, the agreement covers one ophthalmology biosimilar as a prefilled syringe, while in Australia and New Zealand, it encompasses three biosimilar candidates in immunology and gastroenterology. Sandoz will handle regulatory filings and commercialization while Alvotech retains development, clinical activities, and manufacturing responsibilities.

02/02/2026, 3:00 AM • GlobeNewswire

EirGenix Signed The Commercial Licensinse Agreement for It's Second HER2 Biosimilar Asset EG1206A

EirGenix has signed a global exclusive licensing agreement with Sandoz AG for its breast cancer biosimilar EG1206A, covering multiple territories. The agreement includes potential up to $152 million in payments and strengthens their existing collaboration in biosimilar development.

11/12/2025, 3:15 AM • Benzinga

Alvotech Announces Changes in Global Business Development and Commercial Operations Team

Alvotech announced leadership changes in its global business development team, with Anil Okay stepping down, and new appointments of Trisha Durant, Harshika Sarbajna, and Agne Pasko in key commercial roles.

10/22/2025, 5:00 AM • GlobeNewswire

Sandoz welcomes Quebec government support for Boucherville plant modernization project

Sandoz has received government support for a CAD 220 million modernization project at Delpharm's Boucherville pharmaceutical manufacturing facility, involving investments from provincial and federal governments, aimed at improving sterile injectable medicine production.

08/27/2025, 7:30 AM • Benzinga

Saudi Arabia Generic Drugs Market Outlook Report 2025-2033 | Government Cost-Cutting, Local Manufacturing, and Public Awareness Fuel Rapid Growth

Saudi Arabia's generic drugs market is projected to grow from $4.05 billion in 2024 to $8.11 billion by 2033, driven by government cost-cutting initiatives, local manufacturing expansion, and increasing healthcare needs.

08/14/2025, 4:09 AM • GlobeNewswire

Sandoz signs non-binding term sheet with Evotec SE to acquire its Just-Evotec Biologics in-house development and manufacturing capabilities in Toulouse, France

Sandoz plans to acquire Just-Evotec Biologics' development and manufacturing capabilities in Toulouse, France for approximately USD 300 million, aiming to strengthen its biosimilar market position and manufacturing capabilities.

07/30/2025, 1:15 AM • Benzinga